nach oben

Neurogenetics

Erschienen in:

01.11.2007 | Original Article

Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history

verfasst von: Ami R. Rosen, N. Kyle Steenland, John Hanfelt, Stewart A. Factor, James J. Lah, Allan I. Levey

Erschienen in: Neurogenetics | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

This case-control study examined the potential for a common etiology of Parkinson’s disease (PD) and Alzheimer’s disease (AD) using reported family history. Structured interviews were used to collect AD and PD family history from subjects (n = 1531) with AD, PD, AD/PD, or controls. Intergroup analysis compared reported AD and PD family histories in the three case groups to the histories reported in the control group. Intragroup analysis stratified each diagnostic group based on positive family history of AD, then compared the subgroups for a family history of PD. Subjects with AD had a higher risk of having a family history of AD [odds ratio (OR) 2.3; 1.5–3.4] and subjects with PD had a higher risk of having a family history of PD (OR 2.2; 1.2–4.0) as compared to control subjects. Intergroup analyses revealed no significant crossed risk, increased risk of subjects with AD having a family history of PD vs controls and vice versa. Intragroup analysis found that subjects with PD and a family history of AD were more likely to have a family history of PD (OR 1.7; 1.1–2.6) when compared to subjects with PD and no family history of AD. A similar trend was found for subjects with AD (OR 1.7; 0.9–3.1). AD and PD cases each have an increased familial risk of their respective disease. Probands with AD or PD and a family history of either disease have a higher crossed risk of a family history of the other disease. These findings suggest the existence of common genetic and/or environmental factors that predispose to both AD and PD in the subset of cases with positive family history of both neurodegenerative diseases.

Bonifati V, Rizzu P, van Baren MJ et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259CrossRefPubMed

Gasser T, Muller-Myhsok B, Wszolek ZK et al (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet 18:262–265CrossRefPubMed

Goate A, Chartier-Harlin MC, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349:704–706CrossRefPubMed

Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608CrossRefPubMed

Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269:973–977CrossRefPubMed

Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047CrossRefPubMed

Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760CrossRefPubMed

Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977–1981CrossRefPubMed

Valente EM, Bentivoglio AR, Dixon PH et al (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68:895–900CrossRefPubMed

10.

Aarsland D, Andersen K, Larsen JP et al (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392CrossRefPubMed

11.

Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMed

12.

Boller F, Mizutani T, Roessmann U et al (1980) Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 7:329–335CrossRefPubMed

13.

Hakim AM, Mathieson G (1979) Dementia in Parkinson disease: a neuropathologic study. Neurology 29:1209–1214PubMed

14.

Hughes AJ, Daniel SE, Blankson S et al (1993) A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 50:140–148PubMed

15.

Samuel W, Galasko D, Masliah E et al (1996) Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer’s disease. J Neuropathol Exp Neurol 55:44–52CrossRefPubMed

16.

Lippa CF, Smith TW, Nee L et al (1995) Familial Alzheimer’s disease and cortical Lewy bodies: is there a genetic susceptibility factor. Dementia 6:191–194CrossRefPubMed

17.

Aarsland D, Perry R, Brown A et al (2005) Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 58:773–776CrossRefPubMed

18.

Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884PubMed

19.

Fratiglioni L, Ahlbom A, Viitanen M et al (1993) Risk factors for late-onset Alzheimer’s disease: a population-based, case-control study. Ann Neurol 33:258–266CrossRefPubMed

20.

Huff FJ, Auerbach J, Chakravarti A et al (1988) Risk of dementia in relatives of patients with Alzheimer’s disease. Neurology 38:786–790PubMed

21.

Silverman JM, Raiford K, Edland S et al (1994) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer’s disease probands and nondemented spouse controls. Neurology 44:1253–1259PubMed

22.

Hofman A, Schulte W, Tanja TA et al (1989) History of dementia and Parkinson’s disease in 1st-degree relatives of patients with Alzheimer’s disease. Neurology 39:1589–1592PubMed

23.

van Duijn CM, Clayton D, Chandra V et al (1991) Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20(Suppl 2):S13–S20PubMed

24.

Van Duijn CM, Clayton DG, Chandra V et al (1994) Interaction between genetic and environmental risk factors for Alzheimer’s disease: a reanalysis of case-control studies. EURODEM Risk Factors Research Group. Genet Epidemiol 11:539–551CrossRefPubMed

25.

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed

26.

Calne DB, Snow BJ, Lee C (1992) Criteria for diagnosing Parkinson’s disease. Ann Neurol 32(Suppl):S125–S127CrossRefPubMed

27.

Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMed

28.

Farrer LA, O’Sullivan DM, Cupples LA et al (1989) Assessment of genetic risk for Alzheimer’s disease among first-degree relatives. Ann Neurol 25:485–493CrossRefPubMed

29.

Sellbach AN, Boyle RS, Silburn PA et al (2006) Parkinson’s disease and family history. Parkinsonism Relat Disord 12:399–409CrossRefPubMed

30.

Devi G, Ottman R, Tang MX et al (2000) Familial aggregation of Alzheimer disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. Arch Neurol 57:72–77CrossRefPubMed

31.

Marder K, Levy G, Louis ED et al (2003) Familial aggregation of early- and late-onset Parkinson’s disease. Ann Neurol 54:507–513CrossRefPubMed

32.

Payami H, Zareparsi S, James D et al (2002) Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch Neurol 59:848–850CrossRefPubMed

33.

Sveinbjornsdottir S, Hicks AA, Jonsson T et al (2000) Familial aggregation of Parkinson’s disease in Iceland. N Engl J Med 343:1765–1770CrossRefPubMed

34.

Mickel SF, Broste SK, Hiner BC (1997) Lack of overlap in genetic risks for Alzheimer’s disease and Parkinson’s disease. Neurology 48:942–949PubMed

35.

Levy G, Louis ED, Mejia-Santana H et al (2004) Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 61:1033–1039CrossRefPubMed

36.

Elbaz A, McDonnell SK, Maraganore DM et al (2003) Validity of family history data on PD: evidence for a family information bias. Neurology 61:11–17PubMed

37.

Li G, Aryan M, Silverman JM et al (1997) The validity of the family history method for identifying Alzheimer disease. Arch Neurol 54:634–640PubMed

38.

Healy DG, Abou-Sleiman PM, Lees AJ et al (2004) Tau gene and Parkinson’s disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry 75:962–965CrossRefPubMed

39.

Myers AJ, Kaleem M, Marlowe L et al (2005) The H1c haplotype at the MAPT locus is associated with Alzheimer’s disease. Hum Mol Genet 14:2399–2404CrossRefPubMed

Titel: Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history
verfasst von: Ami R. Rosen
N. Kyle Steenland
John Hanfelt
Stewart A. Factor
James J. Lah
Allan I. Levey
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: Neurogenetics / Ausgabe 4/2007
Print ISSN: 1364-6745
Elektronische ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-007-0100-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation

Frataxin gene point mutations in Italian Friedreich ataxia patients

CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations

Acknowledgement to Referees 2006/2007

Novel POMGnT1 mutations define broader phenotypic spectrum of muscle–eye–brain disease